semaglutide arthritis ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism Impact of semaglutide on osteoarthritis

My goal is never to keep patients on medication indefinitely

GHK-Cu is administered as a daily subcutaneous injection with a 30-day cycle followed by a 30-day break

Severe gastrointestinal issues: Individuals with a history of severe gastrointestinal problems, such as gastroparesis or pancreatitis, should steer clear of this medication, as semaglutide can exacerbate these conditions

In Phase 2 trials published in the *New England Journal of Medicine* (2023), participants lost an average of 17.5% of body weight at the highest dose over 24 weeks outperforming tirzepatide and semaglutide in head-to-head data comparisons

"Excluded Drug Reference File FAQ." cms.gov (PDF)

The pharmacological agents for weight loss currently available are only modestly effective